<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436719</url>
  </required_header>
  <id_info>
    <org_study_id>76</org_study_id>
    <nct_id>NCT03436719</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.</brief_title>
  <official_title>Randomized Controlled Trial of Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Scientific Centre of Coloproctology, Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Scientific Centre of Coloproctology, Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, parallel study to determine the efficiency of oral
      antibiotics in reduction of surgical site infection (SSI) in rectal cancer surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing rectal cancer surgery in a single centre will assigned randomly to
      combined preoperative oral antibiotics (metronidazole and erythromycin) and perioperative
      intravenous antibiotics (cefmetazole) (oral+intravenous group) or to perioperative
      intravenous antibiotics (cefmetazole) alone (intravenous group). The primary endpoint is the
      overall rate of SSI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Surgical Site Infection</measure>
    <time_frame>0 to 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Oral with Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral antibiotic</intervention_name>
    <description>Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery</description>
    <arm_group_label>Oral with Intravenous</arm_group_label>
    <other_name>Metronidazole</other_name>
    <other_name>Erythromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous antibiotic</intervention_name>
    <description>Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery</description>
    <arm_group_label>Oral with Intravenous</arm_group_label>
    <arm_group_label>Intravenous</arm_group_label>
    <other_name>Cefoperazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mechanical Bowel Preparation</intervention_name>
    <description>Beginning of MBP at 4 p.m. in a day before surgery</description>
    <arm_group_label>Oral with Intravenous</arm_group_label>
    <arm_group_label>Intravenous</arm_group_label>
    <other_name>polyethylene glycol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a planned of resection of rectum

          -  Have signed approved informed consent form for the study.

        Exclusion Criteria:

          -  Significant simultaneous surgical procedure (e.g., liver resection of metastasis)

          -  Bacterial infection at the time of surgery or antimicrobial therapy up to 4 weeks
             before surgery

          -  Preoperative severe impairment in renal function (creatinine clearance (MDRD) &lt; 30
             ml/min)

          -  Allergy on the study drugs .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evgeny Rybakov, Dr.Med.Sc.</last_name>
    <phone>+7 499 199 86 43</phone>
    <email>erybakov@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>State Scientific Centre of Coloproctology</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Scientific Centre of Coloproctology, Russian Federation</investigator_affiliation>
    <investigator_full_name>Rybakov Evgeny, MD</investigator_full_name>
    <investigator_title>Dr. Med. Sc. State Scientific Centre of Coloproctology, Head of Surgical department of oncoproctology, Moscow, Russian Federation</investigator_title>
  </responsible_party>
  <keyword>Surgical Site Infection</keyword>
  <keyword>Rectal Cancer Surgery</keyword>
  <keyword>Oral Antibiotic</keyword>
  <keyword>Antibiotic Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Cefoperazone</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Sulperazone</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

